Literature DB >> 192679

Contrasting effects of immunosuppression on Theiler's virus infection in mice.

H L Lipton, C D Canto.   

Abstract

In the present study, cyclophosphamide and rabbit anti-mouse thymocyte serum were used to immunosuppress SJL/J mice infected with Theiler's mouse encephalomyelitis virus (TMEV) in order to delineate the potential mechanism(s) of virus-induced cellular injury in this infection. Whereas both immunosuppressive agents produced a significant increase in mortality, this treatment had differing effects on the pathological involvement of gray and white-matter structures in the central nervous system. The central nervous system of immunosuppressed TMEV-infected mice had increased microglial cell proliferation and neuronal necrosis, longer maintenance of high virus levels and spread of virus antigen to involve the neocortex and hippocampal complex. These observations indicate that TMEV causes a cytolotic infection of neurons and possibly other cells in gray matter. In contrast, immunosuppression produced a dramatic reduction in mononuclear inflammatory cells in the leptomeninges and spinal cord white matter of infected mice and prevented demyelination. Further, virus antigen was not detected in the leptomeninges and white matter of immunosuppressed and infected mice. These findings suggest that demyelination of TMEV infection is immune mediated.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 192679      PMCID: PMC421459          DOI: 10.1128/iai.15.3.903-909.1977

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Thymus dependence of viral antigens.

Authors:  W Burns; L C Billups; A L Notkins
Journal:  Nature       Date:  1975-08-21       Impact factor: 49.962

2.  Virus-specific T-cell-mediated cytotoxicity across the H-2 barrier to virus-altered alloantigen.

Authors:  R M Zinkernagel
Journal:  Nature       Date:  1976-05-13       Impact factor: 49.962

3.  ORIGIN OF BRAIN MACROPHAGES IN THE MOUSE.

Authors:  B W KONIGSMARK; R L SIDMAN
Journal:  J Neuropathol Exp Neurol       Date:  1963-10       Impact factor: 3.685

Review 4.  THE VIRAL CARRIER STATE IN ANIMAL CELL CULTURES.

Authors:  D L WALKER
Journal:  Prog Med Virol       Date:  1964

5.  Lysis mediated by T cells and restricted by H-2 antigen of target cells infected with vaccinia virus.

Authors:  U Koszinowski; H Ertl
Journal:  Nature       Date:  1975-06-12       Impact factor: 49.962

6.  Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus.

Authors:  S L Shore; C M Black; F M Melewicz; P A Wood; A J Nahmias
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

7.  Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination.

Authors:  H L Lipton
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

8.  Mouse encephalomyelitis; immunologic studies of a non-infected colony.

Authors:  D J DEAN
Journal:  J Immunol       Date:  1951-03       Impact factor: 5.422

9.  Primary demyelination in Theiler's virus infection. An ultrastructural study.

Authors:  M C Dal Canto; H L Lipton
Journal:  Lab Invest       Date:  1975-12       Impact factor: 5.662

10.  H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus.

Authors:  P C Doherty; R M Zinkernagel
Journal:  J Exp Med       Date:  1975-02-01       Impact factor: 14.307

View more
  29 in total

1.  The interaction of two groups of murine genes determines the persistence of Theiler's virus in the central nervous system.

Authors:  J F Bureau; X Montagutelli; S Lefebvre; J L Guénet; M Pla; M Brahic
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  The relationship between viral RNA, myelin-specific mRNAs, and demyelination in central nervous system disease during Theiler's virus infection.

Authors:  M Yamada; A Zurbriggen; R S Fujinami
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

3.  Glucocorticoid exposure alters the pathogenesis of Theiler's murine encephalomyelitis virus during acute infection.

Authors:  Erin E Young; Thomas W Prentice; Danielle Satterlee; Heath McCullough; Amy N Sieve; Robin R Johnson; Thomas H Welsh; C Jane R Welsh; Mary W Meagher
Journal:  Physiol Behav       Date:  2008-05-07

4.  Role of macrophages during Theiler's virus infection.

Authors:  C P Rossi; M Delcroix; I Huitinga; A McAllister; N van Rooijen; E Claassen; M Brahic
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 5.  Effect of the innate immune response on development of Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Authors:  Julie K Olson
Journal:  J Neurovirol       Date:  2014-07-01       Impact factor: 2.643

6.  Injection of the sciatic nerve with TMEV: a new model for peripheral nerve demyelination.

Authors:  Kristen M Drescher; Steven M Tracy
Journal:  Virology       Date:  2006-10-09       Impact factor: 3.616

7.  Detection of tissue culture-adapted Theiler's virus RNA in spinal cord white matter cells throughout infection.

Authors:  W G Stroop; M Brahic; J R Baringer
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

8.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

9.  Lymphocyte recognition elements on the VP1 protein of Theiler's virus.

Authors:  E J Usherwood; I C Johnston; L J Lovelidge; P Tonks; A A Nash
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

10.  Cytotoxic T cells isolated from the central nervous systems of mice infected with Theiler's virus.

Authors:  M D Lindsley; R Thiemann; M Rodriguez
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.